07:36 uur 25-06-2021

Nucleai en Merck KGaA Darmstadt, Duitsland lanceren samenwerking op het gebied van translationele geneeskunde met behulp van het AI-aangedreven biomarker platform van Nucleai

CHICAGO–(BUSINESS WIRE)– Nucleai (www.nucleaimd.com), een bedrijf in precisiegeneeskunde dat gebruikmaakt van AI-aangedreven beeldanalyse technologie ter ondersteuning van nieuwe, op pathologie gebaseerde biomarker ontwikkeling, en Merck KGaA, Darmstadt, Duitsland, een toonaangevend wetenschaps- en technologiebedrijf , kondigden aan dat ze een langdurige samenwerking zijn aangegaan om Nucleai’s beeldanalyse- en biomarker-ontdekkingsplatform te benutten voor verschillende Merck KGaA, Darmstadt, Duitsland klinische oncologieactiva.

Als onderdeel van de samenwerking zal Merck KGaA, Darmstadt, Duitsland gebruikmaken van Nucleai’s platform voor verkennend onderzoek, met het potentieel om geïdentificeerde op pathologie gebaseerde biomarkers verder te ontwikkelen als begeleidende diagnostiek. De samenwerking zal de technologie van Nucleai verder gebruiken om de analysemogelijkheden van Merck KGaA, Darmstadt, Duitsland uit te breiden, waardoor een snellere doorlooptijd en schaal voor toekomstige studies mogelijk wordt.

Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform

CHICAGO–(BUSINESS WIRE)– Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai’s image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets.

As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies.

Nucleai’s platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system’s spatial characteristics, creating unique and specific histological biomarkers that may help predict patient response. These biomarkers hold the potential to provide better understanding of cancer biology, enable further stratification of responder/non-responder patient populations, and improve the success rate of clinical trials and patient care. To develop its platform, Nucleai leverages proprietary datasets of pathology images and clinical data from leading hospitals and Health Maintenance Organizations (HMOs) in the U.S and Israel.

“We are thrilled to announce another major collaboration with a leading pharmaceutical company like Merck KGaA, Darmstadt, Germany to identify and develop novel biomarkers for their oncology assets. By combining real world and clinical trial datasets, with an integrated and scalable technology platform, we are harnessing the power of AI and big data and setting the standard for future precision medicine collaborations, adds Avi Veidman, CEO and Co-Founder of Nucleai.”

About Nucleai

Nucleai is a precision medicine company that has developed an AI-powered image analysis platform to unlock the power of spatial biology from pathology images. Nucleai’s ATOM platform, built and trained off large-scale proprietary datasets, leverages computer vision and deep neural networks to structure and characterize tissue and cell architecture in pathology images to identify spatial characteristics that predict response to therapy and inform treatment decision. We are currently partnered with leading pharmaceutical companies to discover novel spatial biomarkers, develop pathology-based companion diagnostics assays and drive improved patient outcomes. For more information, please visit www.nucleaimd.com.

Contacts

Jonathan Daniels – VP of Sales
Jonathan@nucleaimd.com

Check out our twitter: @NewsNovumpr